Loncastuximab after short treatment for relapsed mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial studies whether adding loncastuximab after a short course of standard immunochemotherapy can better control mantle cell lymphoma that came back or didn’t respond. It specifically targets people who previously received a BTK inhibitor (or couldn’t tolerate it).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18–84 years old) with a confirmed diagnosis of mantle cell lymphoma (MCL).
- Your lymphoma must have come back or not responded after 1–4 prior treatment lines.
- You must have already had a BTK inhibitor (BTKi), or stopped it because of side effects and still have active disease that needs treatment.
- You must have measurable lymphoma on scans (or only bone marrow involvement is allowed, with required bone marrow tests).
- Your blood and organ labs must be good enough for treatment (for example: low white blood cell counts, platelets, kidney function, and liver blood tests must be within limits).
- You must be able to use reliable birth control (and not be pregnant or breastfeeding).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
This Phase 2 study tests loncastuximab tesirine, a medicine that targets lymphoma cells, in people with marginal zone lymphoma that came back or did not respond to prior treatment. It aims to see how well the treatment can control the disease and shrink lymphoma in the body.
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Refractory Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.